TROG 02.03 - BLADDER (Phase III) - TROG Cancer Research

By w.paterson
23 June, 2021
0 Comments

Randomised phase III trial of radical chemo/radiotherapy vs radiotherapy alone in the definitive management of localised muscle invasive TCC of the urinary bladder

Primary Sponsor

Urological Society of Australasia

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

Trial Chairperson

Dr Kumar Gogna, QRI Mater Centre, QLD

Trial Contact

Kumar Gogna

Clinical Trial Registration

Registration Link

TOPGEAR trial results published in the New England Journal of Medicine

18 September, 2024

TOPGEAR trial findings published in NEJM

18 September 2024: We’re thrilled to announce the release

11 September, 2024

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

11 September 2024: Our 2024 Annual Scientific Meeting was

Join us to raise $35,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Randomised phase III trial of radical chemo/radiotherapy vs radiotherapy alone in the definitive management of localised muscle invasive TCC of the urinary bladder

TROG 03.01 – Oesophagus

TROG 11.A – ANROTAT

Related Post

TOPGEAR trial findings published in NEJM

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

Join us to raise $35,000